Clinical Trial Update: Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis [Phase 4]

View source ↗

Summary

This Phase 4 trial is evaluating whether optimizing golimumab dosing can achieve adequate drug levels and improve response in patients with colitis. The current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: University College Dublin | Conditions: Colitis | Phase 4 | Status: UNKNOWN